Mumbai, February 19, 2025: Pharmaceutical leader Lupin Limited has been awarded an “A-” leadership rating by CDP for its performance in climate change and water security. This distinction reflects Lupin’s proactive stance on environmental issues and dedication to sustainable business practices.
CDP, the foremost global platform for environmental disclosure, enables organizations to evaluate and improve their environmental impact. It champions data transparency as a key driver of environmental action.
Ramesh Swaminathan, Executive Director, Global CFO, and Head – API Plus SBU at Lupin, stated, “Being rated ‘A-’ by CDP in both climate and water categories is an important milestone for us. It confirms our efforts in building a sustainable business while being mindful of our global responsibilities. We value the role CDP plays in guiding organizations toward better environmental performance.”
At Lupin, sustainability is a business imperative, focusing on climate mitigation, employee engagement, ethical sourcing, and innovation that centers around patient health. The latest “A-” CDP scores are a notable step up from the prior year’s ratings of “B” for Climate and “C” for Water.
Lupin’s carbon reduction strategy includes investing in renewable energy, upgrading to energy-efficient infrastructure, and optimizing processes to cut emissions. These steps have contributed to Lupin’s reputation as an environmentally responsible enterprise.
The company’s water strategy includes reusing treated water, rainwater collection, and improving water-use efficiency across manufacturing and operations. These actions ensure long-term water availability and support ecological stability.
Lupin will continue evolving its sustainability roadmap through the adoption of new technologies and forging impactful partnerships aimed at achieving long-term environmental targets.
Supporting this progress, Lupin’s ESG score from S&P Global rose to 76 in 2024, an increase from 69 in 2023, far surpassing the pharma industry average of 30.
About Lupin
Lupin Limited, based in Mumbai, India, is a top-tier global pharmaceutical company present in over 100 countries. The company offers branded and generic medications, complex generics, biosimilars, and APIs. With strongholds in India and the U.S., Lupin serves major therapeutic areas like respiratory, cardiovascular, diabetes, CNS, and women's health. It operates 15 cutting-edge manufacturing facilities and 7 R&D centers worldwide, supported by a team of more than 23,000 professionals. Lupin’s subsidiaries—Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions—advance its mission to deliver accessible, high-quality healthcare worldwide.
Sign in to leave a comment.